ARTICLE | Company News
International Therapeutics other research news
October 15, 2001 7:00 AM UTC
International Therapeutics received a $2 million 2-year Phase II SBIR grant from the National Institute of Allergy and Infectious Diseases to develop small molecule compounds that inhibit translocatio...